Ninth Annual Program Recognizes BostonGene’s Multimodal AI Infrastructure for Reducing Risk and Accelerating Oncology Drug Development

BostonGene, leading developer of AI models for tumor and immune biology, today announced that it has been selected as winner of the “Overall AI-based Analytics Company of the Year” award in the 9^th annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707614322/en/

For nearly a decade, the AI Breakthrough Awards have researched, analyzed and recognized the most important advances in artificial intelligence, and this year's field is the strongest yet. Thousands of nominations from over 20 countries poured in across categories including Agentic AI, Generative AI, Computer Vision, AIOps, Robotics, Natural Language Processing and industry-specific AI applications– underscoring the explosive global growth of AI and its importance as the defining technology of our time.

BostonGene’s integrated platform pairs advanced AI models with CLIA/CAP-certified molecular profiling to transform complex tumor-immune biology into decision-ready insights. By embedding deep transcriptomic and immune system profiling directly into clinical workflows, the platform serves as essential decision infrastructure rather than an exploratory tool. This unified, predictive framework allows biopharmaceutical companies to model treatment response, resistance, and safety in real time. Ultimately, this shifts drug development from retrospective analysis to simulation-guided strategy while accelerating biomarker refinement, patient selection, and portfolio prioritization across the entire drug development lifecycle.

“We are focused on addressing the most persistent, high-stakes challenges in oncology while anticipating and operationalizing key trends. The impact of our approach is reflected in outcomes like improved portfolio focus, reduced development risk, incorporation of immune-driven prediction into pre-treatment strategies to mitigate risk, and sharper patient stratification,” said Andrew Feinberg, President and CEO of BostonGene. “Thank you to AI Breakthrough for recognizing how we are redefining the way clinical and drug development decisions are made by shifting from exploratory analytics to actionable, decision-oriented intelligence.”

“BostonGene delivers a robust, scalable approach to decision intelligence in oncology. Clinical programs experience high attrition rates, with most assets failing to reach the market. Imprecise patient stratification results in suboptimal outcomes and unnecessary toxicity, while development decisions made without sufficient biological filtering at the portfolio level stifle promising therapeutic paths,” said Steve Johansson, managing director, AI Breakthrough. “BostonGene is accelerating the delivery of life-saving therapies across the drug development lifecycle by enabling more informed development strategies, improved patient selection, and reduced uncertainty through AI.”

BostonGene is actively operationalized in collaborative programs with global pharmaceutical companies, including AstraZeneca, Johnson & Johnson, Daiichi Sankyo, Ottimo Pharma, and more, as well as academic and clinical research networks.

About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.

About AI Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Agentic AI, Machine Learning, Generative AI, Robotics, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260707614322/en/

“BostonGene is accelerating the delivery of life-saving therapies across the drug development lifecycle by enabling more informed development strategies, improved patient selection, and reduced uncertainty through AI.”